MONJUVI
Drug
Incyte Corporation
Total Payments
$10.7M
Transactions
36,206
Doctors
9,164
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $766,454 | 5,211 | 3,211 |
| 2023 | $2.1M | 9,423 | 4,274 |
| 2022 | $5.4M | 11,463 | 4,523 |
| 2021 | $2.1M | 8,992 | 3,584 |
| 2020 | $442,280 | 1,117 | 614 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.4M | 1,781 | 40.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.2M | 1,487 | 30.0% |
| Consulting Fee | $1.0M | 323 | 9.7% |
| Food and Beverage | $784,042 | 30,475 | 7.3% |
| Travel and Lodging | $585,473 | 1,682 | 5.5% |
| Grant | $400,000 | 2 | 3.7% |
| Space rental or facility fees (teaching hospital only) | $293,066 | 89 | 2.7% |
| Education | $33,297 | 367 | 0.3% |
Payments by Type
General
$6.4M
34,425 transactions
Research
$4.4M
1,781 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind | MorphoSys AG | $2.4M | 0 |
| A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) | MorphoSys AG | $742,169 | 0 |
| A Phase Ib, open-label, randomized study to assess safety and preliminary efficacy of Tafasitamab in addition to R-CHOP or Tafasitamab plus Lenalidomide in addition to R-CHOP in patients with newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) - First-MIND | MorphoSys AG | $332,523 | 0 |
| A Phase Ib, Open-label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab in Addition to R-CHOP or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) - First-MIND | MorphoSys AG | $321,468 | 0 |
| realMIND: Observational Study of Patients With Relapsed or Refractory DLBCL Starting Second- or Third-line Therapy (realMIND) | MorphoSys AG | $234,470 | 0 |
| A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT) - B-MIND | MorphoSys AG | $203,422 | 4 |
| A Phase II, Two-Cohort, Open-Label, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of MOR00208 Combined with Idelalisib or Venetoclax in Patients with Relapsed or Refractory CLL/SLL Previously Treated with Brutons Tyrosine Kinase (BTK) Inhibitor | MorphoSys AG | $36,379 | 0 |
| A Phase Ib, Open-Label, Multicentre Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) (MINDway) | MorphoSys AG | $34,275 | 0 |
| A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) | MorphoSys, US Inc. | $28,328 | 0 |
| A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) - L-MIND | MorphoSys AG | $20,526 | 2 |
Top Doctors Receiving Payments for MONJUVI
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | West Des Moines, IA | $5.0M | 1,852 |
| , M.D | Hematology & Oncology | San Antonio, TX | $418,607 | 19 |
| , M.D | Hematology & Oncology | Cary, NC | $383,380 | 700 |
| , MD | Medical Oncology | Dallas, TX | $256,863 | 255 |
| , MD | Hematology & Oncology | Indianapolis, IN | $248,586 | 192 |
| , MD | Hematology | Durham, NC | $218,903 | 164 |
| , M.D | Internal Medicine | Loma Linda, CA | $164,120 | 122 |
| , N.P | Acute Care | Los Angeles, CA | $160,706 | 245 |
| , M.D, PHD | Hematology & Oncology | Morristown, NJ | $148,614 | 108 |
| , NP | Nurse Practitioner | Greencastle, IN | $143,150 | 359 |
| Amitkumar Mehta | Hematology & Oncology | Birmingham, AL | $117,809 | 75 |
| , MD PHD | Hematology & Oncology | Seattle, WA | $114,435 | 96 |
| , M.D | Hematology & Oncology | Pittsburgh, PA | $111,805 | 104 |
| , MD | Hematology & Oncology | Washington, DC | $110,946 | 54 |
| , MD | Internal Medicine | Las Vegas, NV | $104,614 | 94 |
| , M.D | Hematology | Philadelphia, PA | $101,240 | 77 |
| , MD | Hospitalist | San Antonio, TX | $94,028 | 94 |
| , M.D | Medical Oncology | Charlotte, NC | $86,609 | 50 |
| , MD | Internal Medicine | Saint Louis, MO | $81,224 | 50 |
| , MD | Internal Medicine | Buffalo, NY | $80,105 | 57 |
| , MD | Medical Oncology | Mcallen, TX | $78,931 | 84 |
| , MD | Internal Medicine | New Hyde Park, NY | $75,450 | 63 |
| , NP-C | Family | Jackson, MS | $67,377 | 134 |
| , MD | Internal Medicine | Stony Brook, NY | $66,820 | 55 |
| , MD | Internal Medicine | Southfield, MI | $63,979 | 45 |
Ad
Manufacturing Companies
- Incyte Corporation $4.9M
- MorphoSys AG $4.4M
- MorphoSys, US Inc. $1.5M
Product Information
- Type Drug
- Total Payments $10.7M
- Total Doctors 9,164
- Transactions 36,206
About MONJUVI
MONJUVI is a drug associated with $10.7M in payments to 9,164 healthcare providers, recorded across 36,206 transactions in the CMS Open Payments database. The primary manufacturer is Incyte Corporation.
Payment data is available from 2020 to 2024. In 2024, $766,454 was paid across 5,211 transactions to 3,211 doctors.
The most common payment nature for MONJUVI is "Unspecified" ($4.4M, 40.8% of total).
MONJUVI is associated with 10 research studies, including "A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind" ($2.4M).